Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes

PLoS One. 2017 Apr 12;12(4):e0175563. doi: 10.1371/journal.pone.0175563. eCollection 2017.

Abstract

VEGFA is an angiogenic factor secreted by tumors, in particular those with VEGFA amplification, as well as by macrophages and lymphocytes in the tumor microenvironment. Here we sought to define the presence of M1/M2 macrophages, PD-1-positive lymphocytes and PD-L1 tumoral and stromal expression in colorectal cancers harboring VEGFA amplification or chromosome 6 polysomy. 38 CRCs of which 13 harbored VEGFA amplification, 6 with Chr6 polysomy and 19 with neutral VEGFA copy number were assessed by immunohistochemistry for CD68 (marker for M1/M2 macrophages), CD163 (M2 macrophages), programmed death 1(PD-1)- tumor infiltrating and stromal lymphocytes as well as tumoral and stromal PD-1 ligand (PD-L1) expression. CRCs with VEGFA amplification or Chr6 polysomy were associated with decreased M1/M2 macrophages, reduced PD-1-expressing lymphocyte infiltration, as well as reduced stromal expression of PD-L1 at the tumor front. Compared to intermediate-grade CRCs, high-grade CRCs were associated with increased M1/M2 macrophages and increased tumoral expression of PD-L1. Our results suggest that VEGFA amplification or Chr6 polysomy is associated with an altered tumor immune microenvironment.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • B7-H1 Antigen / metabolism
  • Chromosomes, Human, Pair 6 / genetics
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / immunology
  • Female
  • Gene Amplification
  • Gene Dosage
  • Genetic Association Studies
  • Humans
  • Lymphocyte Count
  • Lymphocytes / metabolism*
  • Male
  • Middle Aged
  • Programmed Cell Death 1 Receptor / metabolism*
  • Tumor Microenvironment / immunology
  • Vascular Endothelial Growth Factor A / genetics*

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A

Grants and funding

Salvatore Piscuoglio is funded by Swiss National Science Foundation (Ambizione grant number PZ00P3_168165); The study was supported by grants from Oncosuisse KLS-3639-02-2015 (Luigi Maria Terracciano) and KLS-3169-02-2013 (Luigi Tornillo). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. LT is currently employed by GILab AG. GILab AG provided support in the form of salary for author LT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.